Board of Directors LifeGen Technologies currently has three members on its Board of Directors. Richard Weindruch Ph.D. Tomas A. Prolla Ph.D. Howard V. Raff Ph.D. Director and Co-Founder - Richard Weindruch Ph.D. For 26 years, Dr. Weindruch has studied the retardation of aging by caloric restriction (CR). He earned his B.S. and M.S. in Biology at the University of Illinois (Urbana) and his Ph.D. (1978) in Experimental Pathology at UCLA under the direction of Dr. Roy Walford. He has authored two books and more than 130 scientific articles. In 1988, Drs. Weindruch and Walford published "The Retardation of Aging and Disease by Dietary Restriction," which is widely regarded as the founding text for this growing field.  Director and Co-Founder - Tomas A. Prolla Ph.D. While a doctorate student at the Department of Molecular Biophysics and Biochemistry at Yale University, Dr. Prolla discovered the molecular basis of DNA mismatch repair in eukaryotic organisms, a discovery that led to the identification of several human DNA mismatch repair genes involved in cancer. Dr. Prolla's work currently focuses on a collaborative effort with Dr. Weindruch's laboratory to elucidate the genetic basis of aging through the use of DNA microarrays. As a result of this collaboration, LifeGen's founders have generated the first detailed analysis of the aging process at the genomic level.  Director - Howard V. Raff Ph.D. Dr. Howard V. Raff is a Divisional Vice President and Head of Project Management at Chiron Corporation in Emeryville, California. He earned his doctorate in Immunology and Microbiology from Washington State University in 1976. In 1995, he joined Chiron Corporation as a Senior Project Manager. In his current role, he is responsible for managing Chiron's portfolio of drug development projects with a combined budget of over $100 million. Dr. Raff's complementary experiences in pharmaceutical drug development, business development, and management of large, multi-disciplinary projects make him well-suited to be a Director of LifeGen Technologies.